Buying Tesamorelin in the USA: the Full 1-44 Sequence

Sermorelin, CJC-1295 and tesamorelin all descend from growth hormone-releasing hormone, and all three exist because native GHRH does not survive long enough to be useful as a tool compound. What separates them is the route each takes around that problem. Tesamorelin takes the least common one.

Full length as a deliberate choice

Native GHRH is 44 residues long, but receptor activity is fully contained in the first 29. Truncation to GHRH(1-29) is therefore the obvious economy, and most analogs in this family take it. Tesamorelin does not: it keeps the entire 44-residue chain.

That retention is a decision, not an oversight, and it carries consequences. Residues past position 29 add nothing to receptor activation, but they do shape how the peptide behaves in solution. Helical propensity increases with GHRH chain length, and the helix is the conformation the receptor binds. Whether that shows up as a potency difference is assay-dependent; what it reliably changes is physical behavior, since solubility, aggregation tendency and surface adsorption all differ between a 29-mer and a 44-mer from the same family.

So tesamorelin and the GHRH(1-29) analogs are not one molecule at two lengths as far as bench handling is concerned. They are not equally tolerant of rough treatment in the vial.

Three ways to defeat DPP-4

Dipeptidyl peptidase-4 cuts GHRH between residues 2 and 3, and that one cleavage event inactivates the peptide. Tesamorelin answers it with a trans-3-hexenoyl group fixed to the N-terminus: the acyl group occupies the stretch the protease requires while leaving the receptor-binding determinants untouched. Three approaches are in circulation, and each leaves a different signature in vitro.

• N-terminal acylation, the tesamorelin route. A short unsaturated acyl group blocks the protease site. No albumin dependence is introduced, so potency measured with and without serum should agree fairly closely, which makes the compound comparatively straightforward to characterize.
• Residue substitution, the CJC-1295 route. Non-natural amino acids are placed at the cleavage site and at positions prone to oxidation. Albumin-independent as well, unless a binding group is bolted on.
• Albumin conjugation, CJC-1295 with DAC. A maleimide group forms a covalent bond with cysteine-34 of albumin and builds a circulating reservoir. That same binding pulls a fraction of the compound out of play in any serum-containing assay, so apparent potency falls against a serum-free measurement. Benchmarking a DAC analog against an unmodified one in serum-containing medium will systematically understate the DAC form.

By contrast, sermorelin is GHRH(1-29) with essentially no modification at all, and is correspondingly short-lived. Lining the three up is a tidy demonstration that one stability problem admits several answers; see peptide half-life and how analogs extend it, and CJC-1295 DAC vs no DAC for the conjugation question specifically.

Exposure profile is not a footnote, it is the experiment

GHRH receptor signaling is pulsatile in vivo, and the downstream response tracks the pattern of receptor occupancy at least as closely as it tracks total exposure. Sustained occupancy drives GRK phosphorylation, arrestin recruitment, internalization and desensitization at the receptor. A long-acting analog is therefore not a short-acting one with the clock slowed down; the stimulus it delivers is qualitatively different.

Because of that, analogs with different exposure profiles are asking different questions, and a protocol written around one does not transfer to another. Treating GHRH analogs as an interchangeable class remains the most frequent design error in this area.

The same point bites at the analysis stage. Matching two compounds on total exposure and matching them on peak concentration are two distinct experiments, and the same pair of molecules can produce opposite-looking results depending on which was chosen. Whichever it was needs to be stated outright. Sampling has the same property: one blood draw reports on the sampling schedule as much as on the compound, pulses only appear under frequent serial sampling, and IGF-1 is the customary integrated substitute precisely because it averages the pattern out.

Starting points in the literature: PubMed and the broader GHRH analog literature.

Picking a readout

• cAMP accumulation at the GHRH receptor. GHRHR is Gs-coupled, so this is the mechanistically appropriate assay. Putting a GHRH analog into a calcium assay and reporting a flat line is a category error rather than a result; calcium belongs to the secretagogue receptor.
• Growth hormone release from primary pituitary culture. The standard in vitro measure. Dispersed cells receive no hypothalamic input, so somatostatin tone is absent and part of the in vivo separation between compound classes vanishes with it.
• Perifusion. Continuous-flow culture that permits timed exposure and washout, and far more informative than static culture whenever kinetics are the question.
• IGF-1. Quieter than growth hormone, but an integrator, and it will not tell a pulsatile pattern apart from a continuous one delivering the same total.
• Additivity with a secretagogue. GHRHR and GHS-R1a are distinct receptors running distinct second messengers, so combining them yields a response greater than either alone. That additivity works as a mechanistic control on receptor assignment; see GHRH analogs and growth hormone secretagogues compared.

Characterizing a long acylated sequence

A 44-residue acylated peptide raises analytical questions a short one never does.

• The calculated mass has to include the acyl group. Leaving it out is a common arithmetic slip, and it can make a correct certificate look wrong or an incorrect one look fine.
• RP-HPLC purity reported with gradient, column and detection wavelength. A 44-mer generates many deletion sequences, they elute near the main peak, and a steep gradient buries them. This is exactly the situation where a headline purity number with no conditions attached tells you nothing.
• Aggregation state. Long amphipathic sequences aggregate, and an aggregated stock reports the wrong concentration into every assay downstream. Size-exclusion chromatography or dynamic light scattering will show it; a cell assay will not.
• Net peptide content, which matters more as the peptide lengthens because counterion mass scales with the number of charged residues. See net peptide content explained.
• Oxidation. More methionine and tryptophan means more oxidation sites, and a plus-16 satellite on the MS trace is the tell. See deletion, truncation and oxidation impurities.

Getting a 44-mer into solution intact

Tesamorelin is longer than most of what sits in a research catalog, and length correlates with aggregation on reconstitution. The habits that prevent it are simple ones.

• Wet the cake first. Run solvent slowly down the vial wall and leave it to stand. Aiming a stream at a lyophilized cake of a long peptide reliably produces aggregate.
• Skip the vortex and the sonicator. Both apply shear, and both encourage aggregation in long sequences. Gentle inversion and patience instead.
• Stay near neutral pH unless solubility forces otherwise, and inspect for clarity against a dark background before use, because fine aggregate is easy to overlook.
• Aliquot at once, and never thaw the same tube twice.
• Use low-binding plasticware at low working concentrations, where adsorption of a long peptide to surfaces is a genuine loss.
• Keep it out of the light, and track the age of the solution rather than the age of the vial.

Solvent choice is covered in choosing a reconstitution solvent, aliquoting practice in aliquoting and vial entry, and conditions generally in storage and stability.

The three side by side

These are the three names that keep recurring, and the useful framing is that they separate on two axes rather than one: how cleavage is blocked, and whether albumin is in the picture.

• Sermorelin – GHRH(1-29), essentially unmodified. Short-lived, and therefore the nearest available approximation to a native pulse.
• CJC-1295 without DAC – substituted for cleavage resistance, no albumin binding. Longer-lived than sermorelin, still short next to the DAC form.
• CJC-1295 with DAC – covalent albumin binding on top, with a much longer exposure profile and the in vitro caveat noted above.
• Tesamorelin – full-length, acylated at the N-terminus, cleavage-resistant without any albumin dependence.

Any comparison among them must keep the exposure question explicit, or it ends up measuring pharmacokinetics while presenting itself as pharmacology.

Abbreviations used above

• GHRH – growth hormone-releasing hormone; a 44-residue hypothalamic peptide.
• GHRH(1-29) – the N-terminal fragment that carries full receptor activity.
• GHRHR – the receptor; a class B1 GPCR, Gs-coupled, read out through cAMP.
• DPP-4 – dipeptidyl peptidase-4; cleaves between residues 2 and 3 and inactivates the peptide.
• DAC – drug affinity complex; the albumin-binding maleimide group on one CJC-1295 form.
• Somatotroph – the anterior pituitary cell type that synthesizes and secretes growth hormone.
• Perifusion – continuous-flow culture allowing timed exposure and washout.

Product: Tesamorelin 10mg; related material in GHS compounds, with background in GHRH analogs vs secretagogues and handling notes in choosing a reconstitution solvent.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page constitutes medical advice or a suggestion of human or veterinary use. Analytical documentation is published where it is available.

Deciding which GHRH analog to order? See our three-way GHRH analog buying guide.